JAK3 binds JAK3 inhibitors

Janus Kinase 3 (JAK3) binds and is inhibited by several small molecule drugs (Clark et al. 2014, Changelian et al. 2003, Flanagan et al. 2010, Dhillon 2017, Chi et al. 2020). The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases. Drugs that inhibit these kinases such as baricitinib, tofacitinib, ruxolitinib and tofacitinib are thus plausible candidates for treatment of severe host inflammatory reactions to viral infection (Peterson et al. 2020, Richardson et al. 2020).

Janus 激酶 3 (JAK3) 与多种小分子药物（如 Clark 等人于 2014 年、Changelian 等人于 2003 年、Flanagan 等人于 2010 年、Dhillon 于 2017 年、Chi 等人于 2020 年所报道）结合并被抑制。Janus 激酶家族（JAKs）是一类细胞内酪氨酸激酶，在众多参与炎症性疾病发病机制的细胞因子信号传导中发挥着至关重要的作用。因此，如巴瑞替尼、托法替尼、鲁索替尼和托法替尼等抑制这些激酶的药物，对于治疗病毒感染导致的严重宿主炎症反应具有潜在的疗效（Peterson 等人于 2020 年、Richardson 等人于 2020 年所述）。